CD274 and non-small cell lung carcinoma: Despite these discoveries, the associations of TMB, PD-L1 expression and CNgain burden with neoadjuvant immunotherapy need to be validated in large cohorts with more NSCLC patients, e.g., phase II or III clinical trials.